Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 29;5(1):e451.
doi: 10.1002/mco2.451. eCollection 2024 Jan.

Immunotherapy against lung cancer does not need to compromise the outcomes of COVID-19

Affiliations

Immunotherapy against lung cancer does not need to compromise the outcomes of COVID-19

Jiadi Gan et al. MedComm (2020). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
(A) Swimmer's plot of disease course and immunotherapy after COVID‐19 infection in the three patients (P1–P3). (B) Computed tomography of the chest of P1–P3 before and after immunotherapy. Brown arrows indicate pulmonary tumors. P1, patient 1; P2, patient 2; P3, patient 3.

Similar articles

Cited by

References

    1. World Health Organization . WHO coronavirus (COVID‐19) dashboard. Accessed September 27, 2023. https://covid19.who.int/
    1. Abbasi J. What to know about EG.5, the latest SARS‐CoV‐2 “Variant of Interest”. JAMA. 2023;b330(10):900‐901. - PubMed
    1. Yaddanapudi LN. Comorbidities and COVID‐19. J Anaesthesiol Clin Pharmacol. 2020;36(1):S18‐S20.Suppl. - PMC - PubMed
    1. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID‐19‐infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894‐901. - PMC - PubMed
    1. Tan Y, Tang F. SARS‐CoV‐2‐mediated immune system activation and potential application in immunotherapy. Med Res Rev. 2021;41(2):1167‐1194. - PubMed

LinkOut - more resources